Baird Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $38
Analyst Ratings For EyePoint Pharmaceuticals
H.C. Wainwright Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $30
Positive Outlook for EyePoint Pharmaceuticals: Phase 3 LUGANO Trial for DURAVYU Boosts Buy Rating
Capital One Financial Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $35
Scotiabank Initiates Coverage On EyePoint Pharmaceuticals With Sector Outperform Rating, Announces Price Target of $18
Mizuho Securities Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating
EyePoint Pharmaceuticals (EYPT) Receives a Buy From Mizuho Securities
Capital One Financial Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $35
EyePoint Pharmaceuticals Price Target Announced at $15.00/Share by Jefferies
Jefferies Initiates EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Announces Target Price $15
Outperform Rating Reaffirmed for EyePoint Pharmaceuticals Amidst Promising Duravyu Developments
EyePoint Pharmaceuticals Analyst Ratings
JP Morgan Maintains Overweight on EyePoint Pharmaceuticals, Lowers Price Target to $29
J.P. Morgan Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Cuts Target Price to $29
Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Sarepta Therapeutics (SRPT) and Intra-Cellular Therapies (ITCI)
Optimistic 'Buy' Rating for EyePoint Pharmaceuticals Amidst Promising DURAVYU Trial Prospects
Buy Rating Justified by EyePoint Pharmaceuticals' Strong Financials and Promising DURAVYU Trials
EyePoint Pharmaceuticals Earns Buy Rating on Duravyu's Promising Efficacy and Safety Profile
Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Maintains $28 Price Target